5-Amino-1MQ
Also known as: 5-Amino-1-methylquinolinium, NNMT inhibitor
Overview
5-Amino-1MQ is a small-molecule methylquinolinium derivative that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that consumes NAD+ precursors and regulates cellular energy metabolism. While technically a small molecule rather than a classical peptide, it is often discussed alongside peptide therapies due to its metabolic effects. By blocking NNMT, it prevents wasteful methylation of nicotinamide, preserving NAD+ availability and activating longevity-associated pathways.
Mechanism of Action
5-Amino-1MQ inhibits NNMT, the enzyme that methylates nicotinamide (a NAD+ breakdown product) using S-adenosylmethionine (SAM). NNMT overactivity in aging and obesity drains both NAD+ precursors and methyl groups. Inhibition leads to: 1.2-1.6 fold increase in cellular NAD+ in adipocytes; SIRT1 activation (the 'longevity gene') through greater NAD+ availability; white-to-brown adipose tissue conversion (beige adipogenesis) via histone methylation changes; AMPK-related pathway activation mimicking caloric restriction; and improved mitochondrial efficiency and muscle endurance in aged mice.
Potential Benefits
- NAD+ preservation and elevation (1.2-1.6 fold in preclinical models)
- Reversal of diet-induced obesity in mouse models
- Promotion of beige/brown fat conversion enhancing thermogenesis
- SIRT1 activation supporting longevity-associated gene programs
- Improved muscle endurance and recovery in aged mice
- Reduction of insulin resistance and adipose inflammation
- Synergistic with NAD+ precursor therapy (NMN, NR) for sustained effects
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 50-200 mg/day oral |
| Beginner | 50 mg/day |
| Intermediate | 100-150 mg/day |
| Advanced | 200 mg/day |
| Cycle Duration | 4-8 weeks |
| Cycle Off | 4 weeks |
5-Amino-1MQ is an oral small molecule NNMT inhibitor. Very early-stage experimental compound with limited human data. Dosing is extrapolated from preclinical models. Weight-based dosing from mouse studies suggests ~50 mg/day as human starting dose equivalent.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral Moderate
Oral administration used in preclinical studies; human bioavailability not formally characterized
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving 5-Amino-1MQ:
Metabolic Fat Loss Stack
NNMT inhibition combined with GLP-1 appetite suppression for comprehensive fat loss
5-Amino-1MQ targets fat cell NAD+ metabolism and NNMT; Semaglutide addresses central appetite regulation. Different but complementary mechanisms.
Mitochondrial + Fat Loss Stack
NNMT inhibition, AMPK activation, and NAD+ restoration for metabolic optimization
5-Amino-1MQ inhibits NNMT, freeing up methyl donor capacity and raising NAD+; MOTS-c and NAD+ further amplify these mitochondrial and metabolic effects.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | N/A — oral capsules or powder |
|---|---|
| BAC Water | N/A — oral formulation |
| Storage | Store at room temperature 15-25°C; protect from moisture and light |
| Shelf Life | 24 months sealed |
Need exact syringe measurements?
Amino Acid Sequence
N/A (small molecule: C10H10N2)
Side Effects & Safety
- Limited human safety data
- Theoretical epigenetic effects from altered SAM availability
- Possible interactions with methylation-dependent pathways
Synergistic Compounds
The following compounds have been studied alongside 5-Amino-1MQ for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]